| Business Summary | | Endovasc
Ltd.
develops,
markets,
and
licenses
biopharmaceutical
products,
particularly
liposomal
drug
delivery
methods,
for
the
human
healthcare
industry.
Endovasc
develops
liposomes,
which
are
microscopic
cell-like
spheres
composed
of
a
thin,
durable
lipid
membrane
surrounding
a
hollow
compartment.
Liposomes
entrap
and
protect
drugs
from
degradation
in
the
blood
stream
and
can
be
engineered
to
regulate
the
transport
of
molecules
across
their
outer
membrane.
Using
this
technology,
the
Company
is
developing
products
that
deliver
drugs
to
their
intended
target
and
release
them
with
efficiency
and
control.
The
Company's
product
development
currently
is
focused
on
two
product
lines:
Liprostin
and
Nicotine
Receptor
Agonist.
Although
its
current
development
efforts
focus
on
vascular
(heart
and
lung)
applications
of
its
products,
the
Company
intends
to
develop
these
technologies
for
use
in
many
medical
treatment
applications. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Endovasc
Ltd.
is
a
biopharmaceutical
company
using
liposomal
drug
delivery
for
products
that
have
already
shown
safety
and
efficacy
in
generic
form,
and
other
products
for
increased
circulation
in
limbs
and
to
the
heart.
For
the
nine
months
ended
3/31/01,
revenue
totaled
$90
thousand,
up
from
$24
thousand.
Net
loss
rose
less
than
1%
to
$1.8
million.
Results
reflect
revenues
from
a
feasibility
study,
offset
by
increased
personnel
and
overhead
expenses. | More
from
Market Guide: Significant
Developments |
| | |
| Position | David Summers, Ph.D. | Chairman,
CEO | Gary Ball | COO,
VP-R&D, Treasurer | Roy Robertson | VP-Bus.
Devel. | M. Dwight Cantrell | Controller,
CFO | Danilo Lasic, Ph.D. | CSO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|